SG11201507142QA - Antisense molecules for treatment of staphylococcus aureus infection - Google Patents
Antisense molecules for treatment of staphylococcus aureus infectionInfo
- Publication number
- SG11201507142QA SG11201507142QA SG11201507142QA SG11201507142QA SG11201507142QA SG 11201507142Q A SG11201507142Q A SG 11201507142QA SG 11201507142Q A SG11201507142Q A SG 11201507142QA SG 11201507142Q A SG11201507142Q A SG 11201507142QA SG 11201507142Q A SG11201507142Q A SG 11201507142QA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- staphylococcus aureus
- antisense molecules
- aureus infection
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786946P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/028855 WO2014144442A2 (en) | 2013-03-15 | 2014-03-14 | Antisense molecules for treatment of staphylococcus aureus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507142QA true SG11201507142QA (en) | 2015-10-29 |
Family
ID=51538326
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201710369RA SG10201710369RA (en) | 2013-03-15 | 2014-03-14 | Antisense molecules for treatment of staphylococcus aureus infection |
| SG11201507142QA SG11201507142QA (en) | 2013-03-15 | 2014-03-14 | Antisense molecules for treatment of staphylococcus aureus infection |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201710369RA SG10201710369RA (en) | 2013-03-15 | 2014-03-14 | Antisense molecules for treatment of staphylococcus aureus infection |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9777274B2 (en) |
| EP (1) | EP2968603B1 (en) |
| JP (1) | JP6600621B2 (en) |
| KR (1) | KR102206573B1 (en) |
| CA (1) | CA2904440C (en) |
| ES (1) | ES2818927T3 (en) |
| IL (1) | IL241249B (en) |
| SG (2) | SG10201710369RA (en) |
| WO (1) | WO2014144442A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016515381A (en) | 2013-03-15 | 2016-05-30 | テチュロン インコーポレイテッド | Antisense molecules for the treatment of Staphylococcus aureus infections |
| WO2016200926A1 (en) * | 2015-06-09 | 2016-12-15 | Techulon Inc. | Peptide nucleic acid molecules for treatment of gram positive bacterial infection |
| WO2019089953A1 (en) * | 2017-11-01 | 2019-05-09 | Techulon Inc. | Peptide nucleic acid molecules for treatment of gram positive bacterial infection |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174870B1 (en) | 1989-12-04 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of papillomavirus |
| US5811232A (en) | 1989-12-04 | 1998-09-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides for Papillomavirus |
| IT1238439B (en) | 1990-01-26 | 1993-07-26 | Prb Packaging Systems Srl | DEVICE FOR THE FORMATION OF VERTICAL STACKS OF ORDERED ITEMS. |
| US5874564A (en) | 1990-03-21 | 1999-02-23 | Isis Pharmaceuticals, Inc. | Reagents and methods for modulating gene expression through RNA mimicry |
| US5652211A (en) | 1991-02-11 | 1997-07-29 | Biosynth S.R.L. | Peptides for neutralizing the toxicity of Lipid A |
| US6713602B1 (en) | 1991-05-24 | 2004-03-30 | Ole Buchardt | Synthetic procedures for peptide nucleic acids |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5641625A (en) | 1992-05-22 | 1997-06-24 | Isis Pharmaceuticals, Inc. | Cleaving double-stranded DNA with peptide nucleic acids |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5521291A (en) | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| GB9211979D0 (en) | 1992-06-05 | 1992-07-15 | Buchard Ole | Uses of nucleic acid analogues |
| US5527675A (en) | 1993-08-20 | 1996-06-18 | Millipore Corporation | Method for degradation and sequencing of polymers which sequentially eliminate terminal residues |
| DE4331012A1 (en) | 1993-09-13 | 1995-03-16 | Bayer Ag | Nucleic acid-binding oligomers with N-branching for therapy and diagnostics |
| GB2284209A (en) | 1993-11-25 | 1995-05-31 | Ole Buchardt | Nucleic acid analogue-induced transcription of RNA from a double-stranded DNA template |
| US6737248B2 (en) | 1996-01-05 | 2004-05-18 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
| US6593114B1 (en) | 1996-01-05 | 2003-07-15 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6107470A (en) | 1997-05-29 | 2000-08-22 | Nielsen; Peter E. | Histidine-containing peptide nucleic acids |
| US6380370B1 (en) | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| DE19740672A1 (en) | 1997-09-16 | 1999-03-18 | Hoechst Ag | Rhodium-based hydroformylation catalyst |
| DE59813787D1 (en) | 1997-09-27 | 2006-12-14 | Evotec Ag | METHOD FOR IDENTIFYING A NUCLEIC ACID |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| US8211468B2 (en) | 1999-06-07 | 2012-07-03 | Arrowhead Madison Inc. | Endosomolytic polymers |
| US6703492B1 (en) | 1999-11-09 | 2004-03-09 | Smithkline Beecham Corporation | Staphylococcus epidermidis nucleic acids and proteins |
| CA2396068A1 (en) | 2000-01-04 | 2001-07-12 | Avi Biopharma, Inc. | Antisense antibacterial cell division composition and method |
| WO2001076636A2 (en) * | 2000-04-06 | 2001-10-18 | Pantheco A/S | Pharmaceutical composition of modified pna molecules |
| US20080242627A1 (en) | 2000-08-02 | 2008-10-02 | University Of Southern California | Novel rna interference methods using dna-rna duplex constructs |
| US8138383B2 (en) | 2002-03-11 | 2012-03-20 | Arrowhead Madison Inc. | Membrane active heteropolymers |
| WO2004044136A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2’-modified nucleosides for use in gene modulation |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| JP2004236602A (en) * | 2003-02-06 | 2004-08-26 | Dainippon Pharmaceut Co Ltd | Method for screening inhibitor to factor involving bacterial cell division |
| US20050026189A1 (en) | 2003-05-29 | 2005-02-03 | Liangsu Wang | Microbial operons |
| AU2004274021B2 (en) | 2003-09-18 | 2009-08-13 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
| EP1687017B1 (en) | 2003-10-24 | 2013-03-06 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
| US8372966B2 (en) | 2003-12-19 | 2013-02-12 | University Of Cincinnati | Oligonucleotide decoys and methods of use |
| US7514530B2 (en) | 2004-04-26 | 2009-04-07 | Centre National De La Recherche Scientifique | Peptide carrier for delivering siRNA into mammalian cells |
| US20060040882A1 (en) | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
| WO2006044716A2 (en) | 2004-10-15 | 2006-04-27 | Washington University In St.Louis | CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ('PNAs') WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| FR2877946B1 (en) | 2004-11-12 | 2011-02-11 | Commissariat Energie Atomique | MAUROCALCIN-DERIVED PEPTIDES FOR USE AS VECTORS FOR INTRACELLULAR ADDRESSING OF MOLECULES OF INTEREST |
| AU2006339072A1 (en) | 2005-03-14 | 2007-10-25 | Board Of Regents Of The University Of Texas System | Bioactive FUS1 peptides and nanoparticle-polypeptide complexes |
| EP1915161B1 (en) | 2005-07-13 | 2017-04-26 | Sarepta Therapeutics, Inc. | Antisense antibacterial method and compound |
| DE102005051366A1 (en) | 2005-10-25 | 2007-04-26 | Degussa Gmbh | Drug delivery systems |
| WO2007049731A1 (en) | 2005-10-28 | 2007-05-03 | Mitsubishi Tanabe Pharma Corporation | Novel cell membrane-permeable peptide |
| CA2632451C (en) | 2005-12-06 | 2015-11-03 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US7579318B2 (en) | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US8021665B2 (en) * | 2005-12-09 | 2011-09-20 | Trius Therapeutics, Inc. | Identification and application of antibiotic synergy |
| US8501478B2 (en) | 2006-06-15 | 2013-08-06 | University Of Cincinnati | Trehalose click polymers for delivery of biologically active molecules |
| US8377898B2 (en) | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| AR069704A1 (en) | 2007-12-18 | 2010-02-10 | Alcon Res Ltd | SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME |
| WO2012174543A2 (en) | 2011-06-16 | 2012-12-20 | Virginia Tech Intellectual Properties, Inc. | Phosphonium-containing polyelectrolytes for nonviral gene delivery |
| EP2969011A4 (en) | 2013-03-15 | 2017-03-01 | Techulon Inc. | Rapidly adaptable nano therapeutics for treatment of infectious disease |
| JP2016515381A (en) | 2013-03-15 | 2016-05-30 | テチュロン インコーポレイテッド | Antisense molecules for the treatment of Staphylococcus aureus infections |
-
2014
- 2014-03-14 SG SG10201710369RA patent/SG10201710369RA/en unknown
- 2014-03-14 KR KR1020157028885A patent/KR102206573B1/en active IP Right Grant
- 2014-03-14 US US14/777,011 patent/US9777274B2/en active Active
- 2014-03-14 CA CA2904440A patent/CA2904440C/en not_active Expired - Fee Related
- 2014-03-14 WO PCT/US2014/028855 patent/WO2014144442A2/en active Application Filing
- 2014-03-14 SG SG11201507142QA patent/SG11201507142QA/en unknown
- 2014-03-14 JP JP2016502925A patent/JP6600621B2/en active Active
- 2014-03-14 EP EP14762223.7A patent/EP2968603B1/en active Active
- 2014-03-14 ES ES14762223T patent/ES2818927T3/en active Active
-
2015
- 2015-09-07 IL IL241249A patent/IL241249B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2904440A1 (en) | 2014-09-18 |
| KR102206573B1 (en) | 2021-01-25 |
| US9777274B2 (en) | 2017-10-03 |
| IL241249A0 (en) | 2015-11-30 |
| KR20150139532A (en) | 2015-12-11 |
| JP2016515518A (en) | 2016-05-30 |
| EP2968603B1 (en) | 2020-06-24 |
| WO2014144442A3 (en) | 2014-11-27 |
| SG10201710369RA (en) | 2018-01-30 |
| WO2014144442A2 (en) | 2014-09-18 |
| JP6600621B2 (en) | 2019-10-30 |
| ES2818927T3 (en) | 2021-04-14 |
| IL241249B (en) | 2020-09-30 |
| EP2968603A2 (en) | 2016-01-20 |
| CA2904440C (en) | 2021-09-07 |
| US20160177309A1 (en) | 2016-06-23 |
| EP2968603A4 (en) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258886A (en) | Methods of treating and preventing staphylococcus aureus infections and associated conditions | |
| HK1244197A1 (en) | System for glaucoma treatment | |
| HK1216389A1 (en) | Methods of treating topical microbial infections | |
| HK1219221A1 (en) | Dressing for wound treatment | |
| HK1216421A1 (en) | Therapeutic compounds for the treatment of viral infections | |
| PT3409667T (en) | Amide compounds for the treatment of hiv infections | |
| BR112014028633A2 (en) | amd treatment using aav sflt-1 | |
| FI20125146A (en) | PROCEDURES FOR CELLULOSAMAS TREATMENT | |
| IL243403A0 (en) | Treatment for seeds disinfection | |
| EP2977014A4 (en) | Catheter for treatment of sinusitis | |
| BR112016007757A2 (en) | antibacterial derivatives of 2h-indazole | |
| HK1207981A1 (en) | Methods of treating and preventing staphylococcus aureus infections and associated conditions | |
| EP2986342A4 (en) | Antimicrobial catheters | |
| HK1206203A1 (en) | Use of delphinidin against staphylococcus aureus | |
| IL241249B (en) | Antisense molecules for treatment of staphylococcus aureus infection | |
| IL241226A0 (en) | Antisense molecules for treatment of staphylococcus aureus infection | |
| EP2986294A4 (en) | Compounds for treatment of pain | |
| IL244862B (en) | Wound treatment composition | |
| BR112017017489A2 (en) | antimicrobial treatment solutions | |
| EP2986295A4 (en) | Compounds for treatment of pain | |
| AU2013905016A0 (en) | Treatment of animal fibres | |
| GB201320653D0 (en) | Treatment of plants | |
| GB201302147D0 (en) | Antimicrobial treatments for skin | |
| GB201303329D0 (en) | Preparation of antibacterial bisbenzimidazoles | |
| GB201307529D0 (en) | Speed treatment |